<!DOCTYPE html><html><head><title>Help for package ph2bayes</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/themes/prism.min.css" rel="stylesheet" />
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.css">
<script type="text/javascript">
const macros = { "\\R": "\\textsf{R}", "\\code": "\\texttt"};
function processMathHTML() {
    var l = document.getElementsByClassName('reqn');
    for (let e of l) { katex.render(e.textContent, e, { throwOnError: false, macros }); }
    return;
}</script>
<script defer src="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.js"
    onload="processMathHTML();"></script>
<link rel="stylesheet" type="text/css" href="R-nav.css" />
</head><body><div class="container"><nav class="package" aria-label="Topic Navigation">
<div class="dropdown-menu">
<h1>Package {ph2bayes}</h1>
<h2>Contents</h2>
<ul class="menu">
<li><a href='#ph2bayes-package'><p>The 'ph2bayes' package</p></a></li>
<li><a href='#postprob'><p>The posterior probability criterion function</p></a></li>
<li><a href='#predprob'><p>The predictive probability criterion function</p></a></li>
<li><a href='#stopbound_post'><p>The stopping boundaries based on Thall and Simon's criterion</p></a></li>
<li><a href='#stopbound_pred'><p>The stopping boundaries based on Lee and Liu's criterion</p></a></li>
</ul>
</div>
<hr>
</nav>
<main>
<table>
<tr>
<td>Type:</td>
<td>Package</td>
</tr>
<tr>
<td>Title:</td>
<td>Bayesian Single-Arm Phase II Designs</td>
</tr>
<tr>
<td>Version:</td>
<td>0.0.2</td>
</tr>
<tr>
<td>Description:</td>
<td>An implementation of Bayesian single-arm phase II design methods for binary outcome based on posterior
  probability (Thall and Simon (1994) &lt;<a href="https://doi.org/10.2307%2F2533377">doi:10.2307/2533377</a>&gt;) and predictive probability (Lee and Liu (2008) &lt;<a href="https://doi.org/10.1177%2F1740774508089279">doi:10.1177/1740774508089279</a>&gt;).</td>
</tr>
<tr>
<td>License:</td>
<td><a href="https://www.r-project.org/Licenses/GPL-3">GPL-3</a></td>
</tr>
<tr>
<td>Imports:</td>
<td>stats, Rcpp (&ge; 0.12.15)</td>
</tr>
<tr>
<td>LinkingTo:</td>
<td>Rcpp</td>
</tr>
<tr>
<td>RoxygenNote:</td>
<td>6.0.1</td>
</tr>
<tr>
<td>NeedsCompilation:</td>
<td>yes</td>
</tr>
<tr>
<td>Packaged:</td>
<td>2018-02-26 06:24:30 UTC; NAGASHIMA</td>
</tr>
<tr>
<td>Author:</td>
<td>Kengo Nagashima <a href="https://orcid.org/0000-0003-4529-9045"><img alt="ORCID iD"src="https://cloud.R-project.org/web/orcid.svg" style="width:16px; height:16px; margin-left:4px; margin-right:4px; vertical-align:middle" /></a>
    [aut, cre]</td>
</tr>
<tr>
<td>Maintainer:</td>
<td>Kengo Nagashima &lt;nshi1201@gmail.com&gt;</td>
</tr>
<tr>
<td>Repository:</td>
<td>CRAN</td>
</tr>
<tr>
<td>Date/Publication:</td>
<td>2018-02-26 11:40:27 UTC</td>
</tr>
</table>
<hr>
<h2 id='ph2bayes-package'>The 'ph2bayes' package</h2><span id='topic+ph2bayes-package'></span><span id='topic+ph2bayes'></span>

<h3>Description</h3>

<p>An implementation of Bayesian single-arm phase II design methods
for binary outcome based on posterior probability and predictive
probability:
Thall and Simon (Biometrics 1994),
Lee and Liu (Clinical Trials 2008).
</p>

<hr>
<h2 id='postprob'>The posterior probability criterion function</h2><span id='topic+postprob'></span>

<h3>Description</h3>

<p>Thall and Simon's criterion function for determining the
trial decision cutoffs based on the posterior probability.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>postprob(y, n, alpha_e, beta_e, alpha_s, beta_s, delta)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="postprob_+3A_y">y</code></td>
<td>
<p>the number of responses among <code class="reqn">n</code> patients treated by the experimental drug at a certain stage of the trial.</p>
</td></tr>
<tr><td><code id="postprob_+3A_n">n</code></td>
<td>
<p>the number of patients treated by the experimental drug at a certain stage of the trial.</p>
</td></tr>
<tr><td><code id="postprob_+3A_alpha_e">alpha_e</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="postprob_+3A_beta_e">beta_e</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="postprob_+3A_alpha_s">alpha_s</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the standard drug.</p>
</td></tr>
<tr><td><code id="postprob_+3A_beta_s">beta_s</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the standard drug.</p>
</td></tr>
<tr><td><code id="postprob_+3A_delta">delta</code></td>
<td>
<p>the minimally acceptable increment of the response rate for the experimental drug compared with the standard drug.</p>
</td></tr>
</table>


<h3>Value</h3>

<table>
<tr><td><code>prob</code></td>
<td>
<p>the posterior probability: <code class="reqn">\Pr(p_E &gt; p_S + \delta | y)</code></p>
</td></tr>
</table>


<h3>References</h3>

<p>Thall, P. F., Simon, R. (1994).
Practical Bayesian guidelines for phase IIB clinical trials.
<em>Biometrics</em> <strong>50</strong>: 337-349.
</p>
<p>Yin, G. (2012).
<em>Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.</em>
New York: Wiley.
</p>

<hr>
<h2 id='predprob'>The predictive probability criterion function</h2><span id='topic+predprob'></span>

<h3>Description</h3>

<p>Lee and Liu's criterion function for determining the
trial decision cutoffs based on the predictive probability.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>predprob(y, n, nmax, alpha_e, beta_e, p_s, theta_t)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="predprob_+3A_y">y</code></td>
<td>
<p>the number of responses among <code class="reqn">n</code> patients treated by the experimental drug at a certain stage of the trial.</p>
</td></tr>
<tr><td><code id="predprob_+3A_n">n</code></td>
<td>
<p>the number of patients treated by the experimental drug at a certain stage of the trial.</p>
</td></tr>
<tr><td><code id="predprob_+3A_nmax">nmax</code></td>
<td>
<p>the maximum number of patients treated by the experimental drug.</p>
</td></tr>
<tr><td><code id="predprob_+3A_alpha_e">alpha_e</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="predprob_+3A_beta_e">beta_e</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="predprob_+3A_p_s">p_s</code></td>
<td>
<p>the the response rate for the standard drug.</p>
</td></tr>
<tr><td><code id="predprob_+3A_theta_t">theta_t</code></td>
<td>
<p>the prespecified target probability; tipically, <code class="reqn">\theta_T = [0.85, 0.95]</code>.</p>
</td></tr>
</table>


<h3>Value</h3>

<table>
<tr><td><code>prob</code></td>
<td>
<p>the predictive probability: <code class="reqn">PP = \sum_{x=0}^{n_{max}-n} P(x | y) I(\Pr(p_E &gt; p_S | y, x) \geq \theta_T) </code></p>
</td></tr>
</table>


<h3>References</h3>

<p>Lee, J. J., Liu, D. D. (2008).
A predictive probability design for phase II cancer clinical trials.
<em>Clinical Trials</em> <strong>5</strong>: 93-106.
</p>
<p>Yin, G. (2012).
<em>Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.</em>
New York: Wiley.
</p>


<h3>Examples</h3>

<pre><code class='language-R'># p. 97, PP = 0.5656
predprob(16, 23, 40, 0.6, 0.4, 0.6, 0.9)
</code></pre>

<hr>
<h2 id='stopbound_post'>The stopping boundaries based on Thall and Simon's criterion</h2><span id='topic+stopbound_post'></span>

<h3>Description</h3>

<p>The stopping boundaries based on Thall and Simon's criterion.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>stopbound_post(theta, type, nmax, alpha_e, beta_e, alpha_s, beta_s, delta)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="stopbound_post_+3A_theta">theta</code></td>
<td>
<p>the cutoff probability: typically, <code class="reqn">\theta = [0.95, 0.99]</code> for superiority, <code class="reqn">\theta = [0.01, 0.05]</code> for futility.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_type">type</code></td>
<td>
<p>type of boundaries: &quot;superiority&quot; or &quot;futility&quot;.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_nmax">nmax</code></td>
<td>
<p>the maximum number of patients treated by the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_alpha_e">alpha_e</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_beta_e">beta_e</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_alpha_s">alpha_s</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the standard drug.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_beta_s">beta_s</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the standard drug.</p>
</td></tr>
<tr><td><code id="stopbound_post_+3A_delta">delta</code></td>
<td>
<p>the minimally acceptable increment of the response rate for the experimental drug compared with the standard drug.
Note: if type = &quot;superiority&quot;, then delta is set to 0.</p>
</td></tr>
</table>


<h3>Value</h3>

<table>
<tr><td><code>boundset</code></td>
<td>
<p>the boundaries set; <code class="reqn">U_n</code> or <code class="reqn">L_n</code></p>
</td></tr>
</table>


<h3>References</h3>

<p>Thall, P. F., Simon, R. (1994).
Practical Bayesian guidelines for phase IIB clinical trials.
<em>Biometrics</em> <strong>50</strong>: 337-349.
</p>
<p>Yin, G. (2012).
<em>Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.</em>
New York: Wiley.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>stopbound_post(0.05, "futility", 40, 0.6, 1.4, 15, 35, 0)
stopbound_post(0.05, "futility", 30, 0.4, 1.6, 10, 40, 0)
stopbound_post(0.95, "superiority", 40, 0.6, 1.4, 15, 35, 0)
</code></pre>

<hr>
<h2 id='stopbound_pred'>The stopping boundaries based on Lee and Liu's criterion</h2><span id='topic+stopbound_pred'></span>

<h3>Description</h3>

<p>The stopping boundaries based on Lee and Liu's criterion.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>stopbound_pred(theta, type, nmax, alpha_e, beta_e, p_s, theta_t)
</code></pre>


<h3>Arguments</h3>

<table>
<tr><td><code id="stopbound_pred_+3A_theta">theta</code></td>
<td>
<p>the cutoff probability: typically, <code class="reqn">\theta = [0.95, 0.99]</code> for superiority, <code class="reqn">\theta = [0.01, 0.05]</code> for futility.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_type">type</code></td>
<td>
<p>type of boundaries: &quot;superiority&quot; or &quot;futility&quot;.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_nmax">nmax</code></td>
<td>
<p>the maximum number of patients treated by the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_alpha_e">alpha_e</code></td>
<td>
<p>the hyperparameter (shape1) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_beta_e">beta_e</code></td>
<td>
<p>the hyperparameter (shape2) of the Beta prior for the experimental drug.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_p_s">p_s</code></td>
<td>
<p>the the response rate for the standard drug.</p>
</td></tr>
<tr><td><code id="stopbound_pred_+3A_theta_t">theta_t</code></td>
<td>
<p>the prespecified target probability; tipically, <code class="reqn">\theta_T = [0.85, 0.95]</code>.</p>
</td></tr>
</table>


<h3>Value</h3>

<table>
<tr><td><code>boundset</code></td>
<td>
<p>the boundaries set: <code class="reqn">U_n</code> or <code class="reqn">L_n</code></p>
</td></tr>
</table>


<h3>References</h3>

<p>Lee, J. J., Liu, D. D. (2008).
A predictive probability design for phase II cancer clinical trials.
<em>Clinical Trials</em> <strong>5</strong>: 93-106.
</p>
<p>Yin, G. (2012).
<em>Clinical Trial Design: Bayesian and Frequentist Adaptive Methods.</em>
New York: Wiley.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>stopbound_pred(0.05, "futility", 40, 0.6, 1.4, 0.3, 0.85)
stopbound_pred(0.05, "futility", 30, 0.4, 1.6, 0.2, 0.85)
stopbound_pred(0.95, "superiority", 40, 0.6, 1.4, 0.3, 0.85)
</code></pre>

</main>

</div>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/prism.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/components/prism-r.min.js"></script>
</body></html>
